Starpharma Holdings Ltd has released a press release.
Quarterly Activities Report & Appendix 4C
Filed with ASX ·
6ix hasn’t read this filing yet.
Starpharma Holdings Limited on 6ix
Story so far
Earlier from Starpharma
- Response to ASX Query Letters
- Starpharma receives $7.1M R&D tax incentive refund
- VIRALEZE Nasal Spray Registered in Indonesia
- Positive AZD0466 clinical data presented by AstraZeneca
- AGM Chairman address and CEO presentation
Later from Starpharma
- Interim Report and Half-Year Financial Results
- HER2-targeted DEP SN38 ADC outperforms in HER2 cancer model
- VIRALEZE Nasal Spray Approved in Malaysia
- Starpharma CEO to retire in 2024
- Clinical Trial Update
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma